公开(公告)号：US11787859B2

公开(公告)日：2023-10-17

申请号：US16642511

申请日：2018-08-28

Applicant: Bristol-Myers Squibb Company

Inventor： Anke Klippel ,  Laurence Celine Menard

IPC: A61K35/17 ,  C07K16/28 ,  G01N33/50 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/2803 ,  G01N33/505 ,  G01N33/68 ,  A61K2039/507 ,  G01N2800/52

Abstract: Provided herein are methods for treating a subject afflicted with a cancer, comprising administering to the subject a TIM3 agonist (e.g., an anti-TIM3 antibody), alone or in conjunction with another immune checkpoint inhibitor (e.g., a PD-1 antagonist), wherein the subject is identified as having a high frequency of TIM3 positive cells (e.g., on the tumor infiltrating inflammatory cells) or soluble TIM3 in peripheral blood. Also provided are methods for assessing the efficacy of a treatment comprising a TIM3 antagonist in a subject afflicted with a cancer, comprising measuring the frequency of TIM3 (and optionally PD-1) positive cells in certain populations of cells and/or the soluble TIM3 in peripheral blood of the subject, wherein a high frequency of TIM3 (and optionally PD-1) positive cells and/or the subject's peripheral blood titer of soluble TIM3 is indicative of the response to the treatment.

公开(公告)号：US20190086405A1

公开(公告)日：2019-03-21

申请号：US16085007

申请日：2017-03-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Laurence Celine Menard ,  Steven G. Nadler

IPC: G01N33/564

Abstract: In certain embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) identifying the subject as having at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (b) administering an agent that inhibits the CD40 or CD28 signaling pathway, thereby treating or preventing lupus in the subject. In other embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) administering an agent that inhibits the CD40 or CD28 signaling pathway; (b) determining whether the agent neutralizes at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (c) adjusting the dosing of the agent in the subject, thereby treating or preventing lupus in the subject.

公开(公告)号：US20230236188A1

公开(公告)日：2023-07-27

申请号：US18152056

申请日：2023-01-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Laurence Celine Menard ,  Steven G. Nadler

IPC: G01N33/564

CPC classification number: G01N33/564 ,  G01N2333/70532 ,  G01N2333/70578 ,  G01N2800/104 ,  G01N2333/70596 ,  G01N2333/70521 ,  G01N2333/70575 ,  G01N2800/52 ,  G01N2800/60

Abstract: In certain embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) identifying the subject as having at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (b) administering an agent that inhibits the CD40 or CD28 signaling pathway, thereby treating or preventing lupus in the subject. In other embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) administering an agent that inhibits the CD40 or CD28 signaling pathway; (b) determining whether the agent neutralizes at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (c) adjusting the dosing of the agent in the subject, thereby treating or preventing lupus in the subject.